OP240 Incidence of hyperkalemia in patients undergoing radiopeptide therapy does not depend on the amount of co-infused amino acid infusion [Abstract]
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 41, Supplement 2, S. S213-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2014
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Springer
- (wann)
-
2014
- Urheber
- DOI
-
10.1007/s00259-014-2901-9
- URN
-
urn:nbn:de:bvb:384-opus4-637536
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wolf, Herta
- Lapa, Constantin Frederik Victor
- Bluemel, Christina
- Buck, Andreas K.
- Herrmann, Ken
- Universität Augsburg
- Springer
Entstanden
- 2014
Ähnliche Objekte (12)
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
OP247 Role of PSMA-PET/CT in biochemical relapse during follow-up of prostate cancer patients [Abstract]
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
OP247 Role of PSMA-PET/CT in biochemical relapse during follow-up of prostate cancer patients [Abstract]
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
OP247 Role of PSMA-PET/CT in biochemical relapse during follow-up of prostate cancer patients [Abstract]
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation